Eunice Kennedy Shriver National Institute of Child Health & Human Development; Notice of Closed Meetings, 75832-75833 [2016-26261]
Download as PDF
75832
Federal Register / Vol. 81, No. 211 / Tuesday, November 1, 2016 / Notices
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Invention;
Availability for Licensing
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The invention listed below is
owned by an agency of the U.S.
Government and is available for
licensing in the U.S. in accordance with
35 U.S.C. 209 and 37 CFR part 404 to
achieve expeditious commercialization
of results of federally-funded research
and development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
FOR FURTHER INFORMATION CONTACT:
Licensing information may be obtained
by communicating with the indicated
licensing contact at the Technology
Transfer and Intellectual Property
Office, National Institute of Allergy and
Infectious Diseases, 5601 Fishers Lane,
Rockville, MD 20852; tel. 301–496–
2644. A signed Confidential Disclosure
Agreement will be required to receive
copies of unpublished scientific data.
SUPPLEMENTARY INFORMATION:
Technology description follows.
SUMMARY:
asabaliauskas on DSK3SPTVN1PROD with NOTICES
A Human Progenitor Mast Cell Line for
Allergic and Fibrotic Research and
Therapeutic Screening
Description of Technology:
Hermansky-Pudlak Syndrome type-1
(HPS-1) is a rare genetic disorder that
affects around 1 in 500,000 people
worldwide and 1 in 1,800 Puerto
Ricans. Patients with HPS-1 display
oculocutaneous albinism, bleeding due
to platelet abnormality, and pulmonary
fibrosis. Those that develop pulmonary
fibrosis often succumb and live no more
than a decade after early onset of
breathing problems.
Scientists at the National Institute of
Allergy and Infectious Diseases (NIAID)
have developed the HPS-1 proMastocyte
(HPM) cell line, containing an HPS-1
mutation. This cell line resembles a
progenitor mast cell with reduced
granule formation, significant
chemotactic ability, and is the first mast
cell line shown to constitutively release
cytokines, chemokines, and most
importantly fibrotic proteins. This cell
line serves as a model to study granule
formation, early mast cell development,
chemotaxis and mechanisms controlling
synthesis of molecules contributing to
fibrosis.
VerDate Sep<11>2014
00:01 Nov 01, 2016
Jkt 241001
The cell line is available as live cells
approximately 3–4 million cells per
sample in a T25 Flask.
Potential Commercial Applications:
• A tool to further understand fibrosis
• A tool to study granule formation,
early mast cell development,
degranulation and chemotaxis
• Screening tool to identify target
compounds for the treatment of
pulmonary fibrosis
Competitive Advantages:
• First progenitor mast cell line known
to produce fibrotic elements
• Progenitor mast cell line with rapid
growth, no cytokine stimulation
needed. Cell doubling time of 2–3
days
Inventors: Arnold S. Kirchenbaum
and Dean D.Metcalfe, both of NIAID.
Publications:
Kirshenbaum AS et al.
Immunophenotypic and
Ultrastructural Analysis of Mast
Cells in Hermansky-Pudlak
Syndrome Type-1: A Possible
Connection to Pulmonary Fibrosis.;
PLoS One. 2016, Jul
26;11(7):e0159177, PMID 27459687
Intellectual Property: HHS Reference
No. E–270–2016/0. Available as a
Biological Material.
Licensing Contact: Dr. Benjamin
Hurley, (240) 669–5092,
benjamin.hurley@nih.gov.
Collaborative Research Opportunity:
The National Institute of Allergy and
Infectious Diseases is seeking statements
of capability or interest from parties
interested in collaborative research to
further develop, evaluate or
commercialize this invention.
For collaboration opportunities,
please contact Dr. Dianca Finch; 240–
669–5503, dianca.finch@nih.gov.
Dated: October 26, 2016.
Suzanne Frisbie,
Deputy Director, Technology Transfer and
Intellectual Property Office, National Institute
of Allergy and Infectious Diseases.
[FR Doc. 2016–26260 Filed 10–31–16; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Amended
Notice of Meeting
Notice is hereby given of a change in
the meeting of the Frederick National
Laboratory Advisory Committee to the
National Cancer Institute, November 16,
2016, 01:00 p.m. to November 16, 2016,
05:30 p.m., National Cancer Institute
PO 00000
Frm 00028
Fmt 4703
Sfmt 4703
Advanced Technology Research Facility
(ATRF), 8560 Progress Drive,
Auditorium Room E1600, Frederick,
MD, 21702 which was published in the
Federal Register on October 24, 2016,
81 FR 73119.
This Notice has been amended to
change the: Meeting date; start and end
times; agenda and type of meeting. The
meeting will now be held on November
16, 2016 from 8:00 a.m. to November 17,
2017, 12:00 p.m. to conduct a site visit
of the Frederick National Laboratory for
Cancer Research and the National
Cancer Institute (NCI) RAS Initiative.
The meeting will be closed to the public
in accordance with the provisions set
forth in sections 552b(c)(4) and
552b(c)(6), Title 5 U.S.C., as amended.
The project/program and the
discussions could disclose confidential
trade secrets or commercial property
such as patentable material, and
personal information concerning
individuals associated with the project/
program, the disclosure of which would
constitute a clearly unwarranted
invasion of personal privacy.
Dated: October 26, 2016.
Melanie J. Gray,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2016–26259 Filed 10–31–16; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Eunice Kennedy Shriver National
Institute of Child Health & Human
Development; Notice of Closed
Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Child Health and Human Development
Special Emphasis Panel, Animal Assisted
Intervention Review.
Date: December 5, 2016.
Time: 8:00 a.m. to 8:00 p.m.
E:\FR\FM\01NON1.SGM
01NON1
75833
Federal Register / Vol. 81, No. 211 / Tuesday, November 1, 2016 / Notices
Agenda: To review and evaluate grant
applications.
Place: Renaissance Mayflower Hotel, 1127
Connecticut Avenue NW., Washington, DC
20036.
Contact Person: Marita R. Hopmann, Ph.D.,
Scientific Review Officer, Division of
Scientific Review, National Institute of Child
Health and Human Development, 6710B
Bethesda Drive, Bethesda, MD 20892, (301)
435–6911, hopmannm@mail.nih.gov.
Name of Committee: National Institute of
Child Health and Human Development
Special Emphasis Panel, Comparative and
Developmental Perspectives on the
Emergence of Cognitive Competence.
Date: December 7, 2016.
Time: 10:00 a.m. to 1:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6710B
Rockledge Drive, Bethesda, MD 20718
(Telephone Conference Call).
Contact Person: Marita R. Hopmann, Ph.D.,
Scientific Review Officer, Division of
Scientific Review, National Institute of Child
Health and Human Development, 6710B
Bethesda Drive, Bethesda, MD 20892, (301)
435–6911, hopmannm@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.864, Population Research;
93.865, Research for Mothers and Children;
93.929, Center for Medical Rehabilitation
Research; 93.209, Contraception and
Infertility Loan Repayment Program, National
Institutes of Health, HHS)
CBPL No.
Dated: October 26, 2016.
Michelle Trout,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2016–26261 Filed 10–31–16; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HOMELAND
SECURITY
U.S. Customs and Border Protection
Accreditation and Approval of Intertek
USA, Inc., as a Commercial Gauger
and Laboratory
U.S. Customs and Border
Protection, Department of Homeland
Security.
ACTION: Notice of accreditation and
approval of Intertek USA, Inc., as a
commercial gauger and laboratory.
AGENCY:
Notice is hereby given,
pursuant to CBP regulations, that
Intertek USA, Inc., has been approved to
gauge and accredited to test petroleum
and petroleum products for customs
purposes for the next three years as of
July 14, 2015.
DATES: Effective Dates: The
accreditation and approval of Intertek
USA, Inc., as commercial gauger and
laboratory became effective on July 14,
2015. The next triennial inspection date
will be scheduled for July 2018.
FOR FURTHER INFORMATION CONTACT:
Approved Gauger and Accredited
SUMMARY:
27–06 ........................................................
D473
27–08 ........................................................
27–09 ........................................................
D86
D4953
27–11 ........................................................
27–13 ........................................................
D445
D4294
27–48 ........................................................
D4052
27–50 ........................................................
27–54 ........................................................
D93
D1796
27–58 ........................................................
N/A ............................................................
D5191
D1319
N/A ............................................................
asabaliauskas on DSK3SPTVN1PROD with NOTICES
D95
D3606
N/A ............................................................
D4815
N/A ............................................................
D5453
00:01 Nov 01, 2016
Jkt 241001
3 .........................
7 .........................
8 .........................
12 .......................
17 .......................
Title
Tank gauging.
Temperature Determination.
Sampling.
Calculations.
Maritime Measurements.
Intertek USA, Inc., is accredited for
the following laboratory analysis
procedures and methods for petroleum
and certain petroleum products set forth
by the U.S. Customs and Border
Protection Laboratory Methods (CBPL)
and American Society for Testing and
Materials (ASTM):
Standard Test Method for Water in Petroleum Products and Bituminous Materials
by Distillation.
Standard Test Method for Sediment in Crude Oils and Fuel Oils by the Extraction
Method.
Standard Test Method for Distillation of Petroleum Products.
Standard Test Method for Vapor Pressure of Gasoline and Gasoline-Oxgenate
Blends (Dry Method).
Standard Test Method for Kinematic Viscosity of Transparent and Opaque Liquids.
Standard Test Method for Sulfur in Petroleum and Petroleum Products by EnergyDispersive X-ray Fluorescence Spectrometry.
Standard Test Method for Density and Relative Density of Liquids by Digital Density Meter.
Standard Test Methods for Flash-Point by Pensky-Martens Closed Cup Tester.
Standard Test Method for Water and Sediment in Fuel Oils by the Centrifuge Method.
Standard Test Method For Vapor Pressure of Petroleum Products.
Standard Test Method for Hydrocarbon Types in Liquid Petroleum Products by Fluorescent Indicator Absorption.
Standard Test Method for Determination of Benzene and Toluene in Finished Motor
and Aviation Gasoline by Gas Chromatography.
Standard Test Method for Determination of MTBE, ETBE, TAME, DIPE, tertiaryAmyl Alcohol and C1 to C4 Alcohols in Gasoline by Gas Chromatography.
Standard Test Method for Determination of Total Sulfur in Light Hydrocarbons,
Spark Ignition Engine Fuel, Diesel Engine Fuel, and Engine Oil by Ultraviolet Fluorescence.
gauger services should request and
receive written assurances from the
PO 00000
API chapters
Title
27–04 ........................................................
VerDate Sep<11>2014
Notice is
hereby given pursuant to 19 CFR 151.12
and 19 CFR 151.13, that Intertek USA,
Inc., 230 Crescent Ave, Chelsea, MA
02150, has been approved to gauge and
accredited to test petroleum and
petroleum products for customs
purposes, in accordance with the
provisions of 19 CFR 151.12 and 19 CFR
151.13. Intertek USA, Inc., is approved
for the following gauging procedures for
petroleum and certain petroleum
products set forth by the American
Petroleum Institute (API):
SUPPLEMENTARY INFORMATION:
ASTM
Anyone wishing to employ this entity
to conduct laboratory analyses and
Laboratories Manager, Laboratories and
Scientific Services Directorate, U.S.
Customs and Border Protection, 1300
Pennsylvania Avenue NW., Suite
1500N, Washington, DC 20229, tel. 202–
344–1060.
Frm 00029
Fmt 4703
Sfmt 4703
entity that it is accredited or approved
by the U.S. Customs and Border
E:\FR\FM\01NON1.SGM
01NON1
Agencies
[Federal Register Volume 81, Number 211 (Tuesday, November 1, 2016)]
[Notices]
[Pages 75832-75833]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2016-26261]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Eunice Kennedy Shriver National Institute of Child Health & Human
Development; Notice of Closed Meetings
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is hereby given of the following
meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute of Child Health and Human
Development Special Emphasis Panel, Animal Assisted Intervention
Review.
Date: December 5, 2016.
Time: 8:00 a.m. to 8:00 p.m.
[[Page 75833]]
Agenda: To review and evaluate grant applications.
Place: Renaissance Mayflower Hotel, 1127 Connecticut Avenue NW.,
Washington, DC 20036.
Contact Person: Marita R. Hopmann, Ph.D., Scientific Review
Officer, Division of Scientific Review, National Institute of Child
Health and Human Development, 6710B Bethesda Drive, Bethesda, MD
20892, (301) 435-6911, hopmannm@mail.nih.gov.
Name of Committee: National Institute of Child Health and Human
Development Special Emphasis Panel, Comparative and Developmental
Perspectives on the Emergence of Cognitive Competence.
Date: December 7, 2016.
Time: 10:00 a.m. to 1:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, 6710B Rockledge Drive,
Bethesda, MD 20718 (Telephone Conference Call).
Contact Person: Marita R. Hopmann, Ph.D., Scientific Review
Officer, Division of Scientific Review, National Institute of Child
Health and Human Development, 6710B Bethesda Drive, Bethesda, MD
20892, (301) 435-6911, hopmannm@mail.nih.gov.
(Catalogue of Federal Domestic Assistance Program Nos. 93.864,
Population Research; 93.865, Research for Mothers and Children;
93.929, Center for Medical Rehabilitation Research; 93.209,
Contraception and Infertility Loan Repayment Program, National
Institutes of Health, HHS)
Dated: October 26, 2016.
Michelle Trout,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2016-26261 Filed 10-31-16; 8:45 am]
BILLING CODE 4140-01-P